192 related articles for article (PubMed ID: 37394976)
1. Effects of social determinants of health on mortality and incident liver-related events and cardiovascular disease in steatotic liver disease.
Chen VL; Song MW; Suresh D; Wadhwani SI; Perumalswami P
Aliment Pharmacol Ther; 2023 Sep; 58(5):537-545. PubMed ID: 37394976
[TBL] [Abstract][Full Text] [Related]
2. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
3. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
Ochoa-Allemant P; Marrero JA; Serper M
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
[TBL] [Abstract][Full Text] [Related]
4. Screening for social determinants of health among populations at risk for MASLD: a scoping review.
Kim RG; Ballantyne A; Conroy MB; Price JC; Inadomi JM
Front Public Health; 2024; 12():1332870. PubMed ID: 38660357
[TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
Moon JH; Jeong S; Jang H; Koo BK; Kim W
EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
[TBL] [Abstract][Full Text] [Related]
6. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
Wakabayashi SI; Tamaki N; Kimura T; Umemura T; Kurosaki M; Izumi N
J Gastroenterol; 2024 Jun; 59(6):494-503. PubMed ID: 38570344
[TBL] [Abstract][Full Text] [Related]
7. Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study.
Aboona MB; Faulkner C; Rangan P; Ng CH; Huang DQ; Muthiah M; Nevah Rubin MI; Han MAT; Fallon MB; Kim D; Chen VL; Wijarnpreecha K
Liver Int; 2024 Jun; 44(6):1316-1328. PubMed ID: 38407554
[TBL] [Abstract][Full Text] [Related]
8. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
[TBL] [Abstract][Full Text] [Related]
9. Social Determinants of Cardiovascular Risk, Subclinical Cardiovascular Disease, and Cardiovascular Events.
Acquah I; Hagan K; Javed Z; Taha MB; Valero-Elizondo J; Nwana N; Yahya T; Sharma G; Gulati M; Hammoud A; Shapiro MD; Blankstein R; Blaha MJ; Cainzos-Achirica M; Nasir K
J Am Heart Assoc; 2023 Mar; 12(6):e025581. PubMed ID: 36926956
[TBL] [Abstract][Full Text] [Related]
10. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study.
Simon TG; Ebrahimi F; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
Cardiovasc Diabetol; 2023 Dec; 22(1):343. PubMed ID: 38093277
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
Enriquez R; Homsi M; Ssekubugu R; Nabukalu D; Zeebari Z; Marrone G; Gigante B; Chang LW; Reynolds SJ; Nalugoda F; Ekström AM; Hagström H; Nordenstedt H
Aliment Pharmacol Ther; 2024 May; 59(9):1111-1121. PubMed ID: 38459720
[TBL] [Abstract][Full Text] [Related]
13. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
[TBL] [Abstract][Full Text] [Related]
14. The relationship between Social Determinants of Health (SDoH) and death from cardiovascular disease or opioid use in counties across the United States (2009-2018).
Rangachari P; Govindarajan A; Mehta R; Seehusen D; Rethemeyer RK
BMC Public Health; 2022 Feb; 22(1):236. PubMed ID: 35120479
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
Kumar J; Mohsin S; Hasan M; Bilal AR; Ali KM; Umer A; Hadi DZM; Nandlal S; Kumar S
Clin Res Hepatol Gastroenterol; 2024 Jan; 48(1):102261. PubMed ID: 38070828
[TBL] [Abstract][Full Text] [Related]
17. Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Wong RJ; Yang Z; Yeoh A; Do A; Ahmed A; Cheung R
Am J Gastroenterol; 2024 Apr; ():. PubMed ID: 38477465
[TBL] [Abstract][Full Text] [Related]
18. Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality.
Kim D; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38740513
[TBL] [Abstract][Full Text] [Related]
19. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
[TBL] [Abstract][Full Text] [Related]
20. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
